Literature DB >> 20839716

Limit the bleeding, limit the pain in total hip and knee arthroplasty.

Richard J Friedman1.   

Abstract

Patients undergoing total hip or knee arthroplasty often sustain significant decreases in hemoglobin and hematocrit, despite modern techniques and shorter operating times. Reasons for the blood loss include raw bony surfaces, vascular inflammatory tissue, and fragile vessels in elderly patients. Acute postoperative anemia has numerous deleterious effects on patients, including delayed rehabilitation, exposure to allogeneic blood transfusions, higher complication rates, and increased pain. The ability to limit the amount of postoperative bleeding may reduce the amount of postoperative pain that patients experience, ultimately resulting in greater patient satisfaction and smoother postoperative rehabilitation. This article focuses on intraoperative techniques available to limit bleeding, thereby minimizing pain and the need for postoperative transfusion. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Year:  2010        PMID: 20839716     DOI: 10.3928/01477447-20100722-62

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  3 in total

Review 1.  Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis.

Authors:  Xuan Jiang; Xin-Long Ma; Jian-Xiong Ma
Journal:  Orthop Surg       Date:  2016-08       Impact factor: 2.071

2.  The effect of peri-operative blood loss on postoperative pain following total knee arthroplasty.

Authors:  Paul Hegarty; Seamus O'Brien; Mike Stevenson; David Beverland
Journal:  J Orthop       Date:  2015-02-23

3.  Risk factors of opioid use associated with an enhanced-recovery programme after total knee arthroplasty.

Authors:  Guorui Cao; Shiqi Xiang; Minglu Yang; Songtao Quan; Junna Yao; Litao Cai; Wei Feng; Xiuli Yang; Hong Xu; Zeyu Huang; Shaoyun Zhang; Chen Yue; Honglue Tan; Fuxing Pei
Journal:  BMC Musculoskelet Disord       Date:  2021-12-20       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.